HCV Treatment
EASL 2011: BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 April 2011 14:02
- Written by Matt Sharp
Most prior non-responders with HCV genotype 1 achieved sustained response with a quadruple combination containing 2 experimental agents plus pegylated interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs -- BMS-790052 and BMS-650032 -- researchers reported at EASL 2011.
EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 14:14
- Written by Liz Highleyman
76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011.
EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 05 April 2011 06:57
- Written by Vertex Pharmaceuticals
The Vertex experimental protease inhibitor telaprevir, taken with pegylated interferon plus ribavirin, increased sustained response in people with all IL28B gene patterns, researchers reported at EASL 2011.
EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 08:05
- Written by Liz Highleyman
Almost all treatment-naive hepatitis C patients treated with Pharmasset's candidate PSI-7977 plus pegylated interferon/ribavirin experienced 12-week sustained response, and more than 90% treated with a PSI-7977 + PSI-938 all-oral combo had undetectable HCV at 14 days, researchers reported at EASL.
Boceprevir Improves Response to Interferon-Based HCV Therapy
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 31 March 2011 17:54
- Written by Liz Highleyman
The HCV protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and prior non-responders, according to findings from 2 studies published in the March 31 New England Journal of Medicine.
More Articles...
- CROI 2011: Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
- CROI 2011: HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
- Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People
- HCV Polymerase Inhibitor INX-189 Gets FDA Fast-Track Status, TMC649128 Enters Phase 1a Trial